The entire panel enters a discussion around histopathology’s shortcomings, ranging from the fact that the NAFLD Activity score does not correlate with liver function to inconsistencies in reading all elements of biopsy.
Stephen Harrison and Jörn Schattenberg join the conversation with questions that focus on patient treatment and drug development.
Scott Friedman reprises key elements from his Paris NASH talk, focusing on Precision Medicine and some key factors that affect hepatic function that Precision Medicine must address.
Scott Friedman, the “Father of Fibrosis”, and Jörn Schattenberg join the Surfers to discuss Scott’s recent Paris NASH and National Liver Congress talks on Precision Medicine, imaging and liver function.
Antaros Medical’s Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. In this section, panel members speculate on the largest, most important conceptual changes that the new imaging approaches can drive in disease knowledge and research.
Antaros Medical’s Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. This conversation revolves around the implications of Lars’s comment that we should track and analyze functioning hepatocyte cells as an excellent marker for liver function.
Antaros Medical’s Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. In this conversation, Lars and Stephen discuss the value of assessing the balance of fibrogenesis and fibrosis in healthy and unhealthy livers.
Antaros Medical’s Chief Scientific Officer Lars Johannson joins Stephen Harrison, Louise Campbell and Roger Green to reprise the key points of his recent Paris NASH talk and comment on several other topics.
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation centers on two issues: driving behavior change and recognizing the scope of the need.
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation centers on how the working group came to be and how they developed this pivotal paper.
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology.
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of “Biggest Stories of NASH Summer.” In this conversation, Roger uses a classical Marketing Research question to help the group sort out the relative impact potential of the ideas they have been discussing.
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of “Biggest Stories of NASH Summer.” In this conversation, Louise Campbell raises two very different points about the earlier conversation.
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of “Biggest Stories of NASH Summer.” In this conversation, Stephen Harrison starts by discussing some issues and insights around the use of FGF-21s and then “hijacks” the conversation to explore a standard practice in histopathology that he would like to change.
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of “Biggest Stories of NASH Summer.” In this conversation, Stephen Harrison provides an image to suggest the enormity of the coming NASH pandemic and Mazen identifies his two biggest stories of summer.
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of “Biggest Stories of NASH Summer” with his own unique slant on recent events and publications.
Professor Manal Abdelmalek joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on NIH’s recent decision to stand up and fund the Liver Cirrhosis Network.
Professor and epidemiologist Dr. Michelle Long joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on the recent paper on prevalence of NAFLD and NASH in an unselected middle-aged population.
Newly-appointed Professor Ian Rowe joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. He focuses on the recent FDA approval of the ELF test for prognosis of cirrhosis.
Ian Rowe, Michelle Long and Manal Abdelmalek reveal what they consider the most important NAFLD/NASH stories of summer.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting. This conversation looks at the Day Two sessions and the overall implications of the meeting.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting. This conversation looks at the session covering fibrosis.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeeting. This conversation looks at sessions covering epidemiology, public response and clinical questions.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting, an event with exciting scientific messages and insights.
